[go: up one dir, main page]

BR9914940A - Método para aperfeiçoar a farmacocinética de tipranavir - Google Patents

Método para aperfeiçoar a farmacocinética de tipranavir

Info

Publication number
BR9914940A
BR9914940A BR9914940-0A BR9914940A BR9914940A BR 9914940 A BR9914940 A BR 9914940A BR 9914940 A BR9914940 A BR 9914940A BR 9914940 A BR9914940 A BR 9914940A
Authority
BR
Brazil
Prior art keywords
tipranavir
pharmacokinetics
improve
improving
pharmaceutically acceptable
Prior art date
Application number
BR9914940-0A
Other languages
English (en)
Inventor
James J Ferry
John R Baldwin
Marie T Borin
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9914940A publication Critical patent/BR9914940A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>MéTODO PARA APERFEIçOAR A FARMACOCINéTICA DE TIPRANAVIR<D> A presente invenção refere-se a um método novo para aperfeiçoar a farmacocinética de tipranavir, que compreende administrar a um ser humano necessitando de tal tratamento uma combinação de uma quantidade terapeuticamente eficaz de tipranavir ou um sal correspondente aceitável do ponto de vista farmacêutico, e uma quantidade terapeuticamente eficaz de ritonavir ou um sal correspondente aceitável do ponto de vista farmacêutico.
BR9914940-0A 1998-11-04 1999-10-29 Método para aperfeiçoar a farmacocinética de tipranavir BR9914940A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04
PCT/US1999/021469 WO2000025784A1 (en) 1998-11-04 1999-10-29 Method for improving the pharmacokinetics of tipranavir

Publications (1)

Publication Number Publication Date
BR9914940A true BR9914940A (pt) 2001-07-10

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914940-0A BR9914940A (pt) 1998-11-04 1999-10-29 Método para aperfeiçoar a farmacocinética de tipranavir

Country Status (13)

Country Link
US (1) US6147095A (pt)
EP (1) EP1126847A1 (pt)
JP (1) JP2002528502A (pt)
CN (1) CN1154491C (pt)
AU (1) AU762349B2 (pt)
BR (1) BR9914940A (pt)
CA (1) CA2346131C (pt)
CO (1) CO5160321A1 (pt)
HK (1) HK1040625B (pt)
MY (1) MY118526A (pt)
PE (1) PE20001296A1 (pt)
TW (1) TW580387B (pt)
WO (1) WO2000025784A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
DK1333810T3 (da) * 2000-10-31 2008-02-04 Boehringer Ingelheim Pharma Orale selvemulgerende doseringsformuleringer af pyranon-protease-inhibitorer
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
KR20050085681A (ko) * 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
WO2004087139A1 (en) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
EP1814547A1 (en) * 2004-11-16 2007-08-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
WO2006055754A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
CA2586501A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
US20060160859A1 (en) * 2004-12-01 2006-07-20 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and GW873140
EP1819335A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
EA201290852A1 (ru) * 2010-04-02 2013-04-30 ФИВКО-1 ЭлЭлСи Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
JP6184943B2 (ja) * 2011-05-30 2017-08-23 オートテリック エルエルシー ポイント・オブ・ケア薬物動態プロフィールによる治療薬モニタリングおよび用量投与のための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
PE20001296A1 (es) 2000-11-23
AU762349B2 (en) 2003-06-26
JP2002528502A (ja) 2002-09-03
AU1440400A (en) 2000-05-22
EP1126847A1 (en) 2001-08-29
CO5160321A1 (es) 2002-05-30
TW580387B (en) 2004-03-21
MY118526A (en) 2004-11-30
CN1154491C (zh) 2004-06-23
HK1040625A1 (en) 2002-06-21
CN1324237A (zh) 2001-11-28
WO2000025784A1 (en) 2000-05-11
US6147095A (en) 2000-11-14
CA2346131A1 (en) 2000-05-11
CA2346131C (en) 2013-01-15
HK1040625B (zh) 2005-04-01

Similar Documents

Publication Publication Date Title
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
YU83502A (sh) Nova farmaceutska smeša
TW264480B (pt)
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
GB0108592D0 (en) Therapeutic agents
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer&#39;s disease
UA41355C2 (uk) Засіб для лікування нейро-сніду
LU91281I2 (fr) Preotact-hormone parathyroïde
AU2003277280A1 (en) Biphenyls and fluorenes as imaging agents in alzheimer&#39;s disease
BG104179A (en) Phanquinon administration for the treatment of the alzheimer&#39;s disease
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
AUPP325398A0 (en) Improved method for eradicating h. pylori
PT1152762E (pt) Utilizacao de desoxipeganina no tratamento da demencia de alzheimer
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
AU2177401A (en) Combination of riluzole and gabapentin and use thereof as medicine
ECSP993206A (es) Metodo para mejorar la farmacocinetica del tipranavir
EP1712231A3 (en) Method for improving the pharmacokinetics of tipranavir
HUP9800835A3 (en) Pharmaceutical composition for treatment of diseases of honey-bees caused by ascophaera apis

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NO DISPOSTO NO INCISO VIII DO ARTIGO 10 DA LEI NO 9.279 DE 14/05/1996 COMBINADO COM O ARTIGO 37 DO MESMO DISPOSITIVO LEGAL.

B12B Appeal: appeal against refusal